Search research articles
Contact Us
Filters
Showing results (91-100 of 133) with videos related to
Page
of 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 27, 2017
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Elizabeth A Griffiths, Pragya Srivastava, Junko Matsuzaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2024
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279
Neil S Horowitz, Wei Deng, Ivy Peterson, et al.
Cancer
|
November 20, 2016
What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study
Bunja J Rungruang, Austin Miller, Thomas C Krivak, et al.
Gynecologic Oncology
|
November 12, 2019
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer
Kathleen N Moore, Austin Miller, Katherine M Bell-McGuinn, et al.
Gynecologic Oncology
|
September 12, 2024
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14
Jubilee Brown, Austin Miller, Laura L Holman, et al.
JAMA Network Open
|
January 11, 2020
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
Xavier Paoletti, Liz-Anne Lewsley, Gennaro Daniele, et al.
Gynecologic Oncology
|
November 28, 2017
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study
Neil S Horowitz, G Larry Maxwell, Austin Miller, et al.
Journal of the National Cancer Institute
|
April 17, 2019
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
Utpal K Mukhopadhyay, Chetan C Oturkar, Christina Adams, et al.
Gynecologic Oncology
|
February 21, 2021
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study
Jessica Gillen, Austin Miller, Katherine M Bell-McGuinn, et al.
Gynecologic Oncology
|
January 6, 2023
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors
Cynthia A Thomson, Tracy E Crane, Austin Miller, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 133) with videos related to
Sort By:
Page
of 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 27, 2017
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Elizabeth A Griffiths, Pragya Srivastava, Junko Matsuzaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2024
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279
Neil S Horowitz, Wei Deng, Ivy Peterson, et al.
Cancer
|
November 20, 2016
What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study
Bunja J Rungruang, Austin Miller, Thomas C Krivak, et al.
Gynecologic Oncology
|
November 12, 2019
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer
Kathleen N Moore, Austin Miller, Katherine M Bell-McGuinn, et al.
Gynecologic Oncology
|
September 12, 2024
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14
Jubilee Brown, Austin Miller, Laura L Holman, et al.
JAMA Network Open
|
January 11, 2020
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
Xavier Paoletti, Liz-Anne Lewsley, Gennaro Daniele, et al.
Gynecologic Oncology
|
November 28, 2017
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study
Neil S Horowitz, G Larry Maxwell, Austin Miller, et al.
Journal of the National Cancer Institute
|
April 17, 2019
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
Utpal K Mukhopadhyay, Chetan C Oturkar, Christina Adams, et al.
Gynecologic Oncology
|
February 21, 2021
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study
Jessica Gillen, Austin Miller, Katherine M Bell-McGuinn, et al.
Gynecologic Oncology
|
January 6, 2023
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors
Cynthia A Thomson, Tracy E Crane, Austin Miller, et al.
Page
of 14